Startups
The Investor Relations website contains information about Ovid Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 4, 2022 | AstraZeneca hands off epilepsy programs to Ovid; Amylyx scores priority review for ALS drug | Still recovering from a setback in its lead program, Ovid Therapeutics has turned to AstraZeneca for a suite of experimental epilepsy drugs. Ovid is paying the Big Pharma partner $5 million in cash and $7.5 million in sto... |
| Mar 4, 2021 | Takeda sichert sich die weltweiten Rechte von Ovid Therapeutics zur Entwicklung und Vermarktung von Soticlestat für die Behandlung von Kindern und Erwachsenen mit Dravet-Syndrom und Lennox-Gastaut-Syndrom | OSAKA (Japan) und NEW YORK--(BUSINESS WIRE)--Mrz 4, 2021-- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) („Takeda“) und Ovid Therapeutics Inc. (NASDAQ: OVID) („Ovid“), ein Biopharma-Unternehmen, das sich mit der Entwicklung vo... |
| Mar 3, 2021 | Takeda obtient les droits mondiaux d'Ovid Therapeutics pour le développement et la commercialisation de Soticlestat pour le traitement des enfants et des adultes atteints du syndrome de Dravet et du syndrome de Lennox-Gastaut | OSAKA, Japon et NEW YORK--(BUSINESS WIRE)--mars 3, 2021-- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) ("Takeda") and Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), une société biopharmaceutique vouée au ... |
| Dec 1, 2020 | Ovid’s treatment for a rare, untreatable disease fails in a key trial | Ovid Therapeutics’ experimental drug for a devastating rare disease proved no better than placebo in a pivotal clinical trial, the company said Tuesday, a bitter disappointment for families dealing with the untreatable condition. The study ... |
| Jul 14, 2020 | Ovid, Angelini sign Europe licensing deal worth up to $232.5M for rare disease drug | Shares of Ovid rose 7% Monday morning following the news and were up 2.7% from their opening price Tuesday afternoon on the Nasdaq. Angelini is a private company with a significant neurology business. Angelini will pay Ovid $20 million upfr... |
| Jun 27, 2019 | Ovid Therapeutics starts Phase III trial in rare neurological disorder | Starting in the third quarter of this year, the study will enroll 60 patients aged 4 to 12, who will be randomized to receive a once-daily dose of either OV101 or placebo. As a primary endpoint, the trial will use the Clinical Global Impres... |
| Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome | OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Mar 3, 2021-- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medic... | |
| Ovid Therapeutics starts Phase III trial in rare neurological disorder | A company developing a drug for a rare neurological disorder that produced encouraging, but mixed results in a prior study has initiated its Phase III trial. New York-based Ovid Therapeutics said Thursday that it had initiated the NEPTUNE s... | |
| Ovid, Angelini sign Europe licensing deal worth up to $232.5M for rare disease drug | A company developing a drug for a rare genetic disease that causes developmental disabilities has made a licensing deal with an Italian firm for exclusive rights in Europe. New York-based Ovid Therapeutics said Monday that it had signed an ... |